biostudies-literatureMinkus CLNEI NIH HHS200-209https://www.ebi.ac.uk/biostudies/studies/S-EPMC8429526biostudies-literatureUnknown229<h4>Purpose</h4>To determine the incidence of and predictive factors for cataract in intermediate uveitis.<h4>Design</h4>Retrospective cohort study.<h4>Methods</h4>Patients were identified from the Systemic Immunosuppressive Therapy for Eye Diseases Cohort Study, in which medical records were reviewed to determine demographic and clinical data of every eye/patient at every visit at 5 participating US tertiary care uveitis centers. The primary outcome was development of vision-compromising cataract as defined by a decrease in visual acuity to 20/40 or less, or requiring cataract surgery. Survival analysis assessed visually defined cataract to avoid bias due to timing of surgery vis-à-vis inflammatory status.<h4>Results</h4>Among 2,190 eyes of 1,302 patients with intermediate uveitis, the cuAmerican journal of ophthalmologyRisk of Cataract in Intermediate Uveitis.PMC8429526R21 EY026717R01 EY014943Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study Research GroupFoster CSPayal ARMinkus CLThorne JERosenbaum JTSen HNBuchanich JMBegum HKacmaz ROKempen JHBhatt NPDreger KAPistilli MJabs DALevy-Clarke GASuhler EBNussenblatt RBFitzgerald TDfalseRisk of Cataract in Intermediate Uveitis.<h4>Purpose</h4>To determine the incidence of and predictive factors for cataract in intermediate uveitis.<h4>Design</h4>Retrospective cohort study.<h4>Methods</h4>Patients were identified from the Systemic Immunosuppressive Therapy for Eye Diseases Cohort Study, in which medical records were reviewed to determine demographic and clinical data of every eye/patient at every visit at 5 participating US tertiary care uveitis centers. The primary outcome was development of vision-compromising cataract as defined by a decrease in visual acuity to 20/40 or less, or requiring cataract surgery. Survival analysis assessed visually defined cataract to avoid bias due to timing of surgery vis-à-vis inflammatory status.<h4>Results</h4>Among 2,190 eyes of 1,302 patients with intermediate uveitis, the cu2021-01-01T00:00:00Z2021 Sep2025-04-04T09:37:18.044Z2025-04-04T09:37:18.044ZS-EPMC84295263371367910.1016/j.ajo.2021.02.032